UNDERSTANDING YOUR DENIAL
Why This Denial Happens
You're Not Alone
Many GLP-1 (a class of weight loss medications) prior authorization (pre-approval) requests are denied initially. The most common reason? Insurers claim the medication isn't "medically necessary"—even when it clearly is.[1]
When your insurer says Wegovy is "not medically necessary," they're claiming one of these things:
They don't recognize obesity as a disease requiring treatment
Some insurers still treat obesity as a "lifestyle choice" rather than the chronic, relapsing disease it is. The AMA, WHO, and CDC all recognize obesity as a medical condition—but insurance policies haven't all caught up.
Your documentation doesn't prove you meet their criteria
Even if you qualify, missing or incomplete documentation can trigger a denial. Common gaps include:
- BMI (body mass index) not documented within the last 30 days
- Comorbidities (related health conditions) not listed with ICD-10 (standard medical diagnosis) codes
- No record of prior weight loss attempts
- Missing lab results
They classify weight loss as "cosmetic"
This is factually incorrect. Wegovy is FDA-approved to treat obesity—a medical condition with serious health consequences including cardiovascular disease, type 2 diabetes, and reduced life expectancy. It's not a cosmetic treatment. In fact, Wegovy is also FDA-approved to reduce cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight.
The good news: Appeals work. With the right documentation and approach, 65%+ of appeals succeed.[2][6] Here's exactly how to do it.
For a complete overview of getting Wegovy covered, see our insurance coverage guide.
Your GLP-1 coverage,
denied approved
Honest Care writes personalized, evidence-backed appeal letters — so you can fight back with confidence.
Need help appealing?
Get Started FreeNEXT STEPS
How to Appeal
Medical necessity denials are highly appealable with proper documentation. Most plans allow 180 days from your denial date to file, but check your denial letter for your specific deadline.[3]
For the complete step-by-step appeal process, see our Wegovy Appeals Guide.
TEMPLATE & KEY ELEMENTS
Letter of Medical Necessity
A Letter of Medical Necessity (LOMN) is the most powerful tool in your appeal. This formal document from your doctor explains why Wegovy is medically required—not optional—for your condition.
What Your LOMN Must Include
- Patient information (name, DOB, member ID, case/reference ID)
- Provider information (name, NPI (National Provider Identifier) number, specialty, contact)
- The exact denial language being appealed
- Clinical rationale for why Wegovy is necessary
- Supporting evidence (trial data, guidelines)
- Clear request for reconsideration
View LOMN Structure Template
HEADER:
[Date] [Medical Director Name] [Insurance Company] [Address] Re: Appeal for [Patient Name] Member ID: [Number] DOB: [Date] Case ID: [Number]
OPENING:
"Dear Medical Director, I am writing to appeal the denial of coverage for Wegovy (semaglutide) for [Patient Name]. The denial stated: '[copy exact denial language].' I respectfully request reconsideration based on the following clinical information demonstrating medical necessity."
CLINICAL SUMMARY:
Include: Current diagnosis (ICD-10 codes), BMI history, weight-related comorbidities with supporting labs, prior treatment attempts and outcomes.
EVIDENCE SECTION:
Cite STEP trials, SELECT trial (cardiovascular benefit), professional guidelines (AACE (American Association of Clinical Endocrinology), Endocrine Society), and FDA approval information.
CLOSING:
"Based on the above clinical evidence, continued obesity without effective treatment poses significant health risks for [Patient Name]. Wegovy is medically necessary to reduce these risks and improve long-term outcomes. Please feel free to contact me at [phone] with any questions. Sincerely, [Provider Name, Credentials] [NPI Number]"
Official resource: Novo Nordisk provides Letter of Medical Necessity templates through novoMEDLINK for healthcare providers.[5]
TRIAL DATA FOR YOUR APPEAL
Clinical Evidence to Include
Strong appeals cite clinical evidence. Here's the data that supports Wegovy's medical necessity:
STEP Trial Results
| Trial | Population | Weight Loss | vs. Placebo |
|---|---|---|---|
| STEP 1 | Obesity without type 2 diabetes (n=1,961) | 14.9% at 68 weeks | vs. 2.4% |
| STEP 2 | Obesity with type 2 diabetes | 9.6% at 68 weeks | vs. 3.4% |
| STEP 4 | Maintenance (n=902) | 17.4% total from baseline | vs. +7% regain |
| STEP 5 | Long-term (104 weeks) | 15.2% | vs. 2.6% |
Source: STEP program clinical trials (NEJM, Lancet)[7]
Cardiovascular Evidence (SELECT Trial)
Key Finding — FDA-Approved CV Indication
The SELECT trial enrolled 17,604 participants with overweight/obesity and established heart disease. Results showed semaglutide 2.4mg reduced the risk of major cardiovascular events—heart attacks, strokes, and cardiovascular death—by 20%. This led to FDA approval of Wegovy injection for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight on March 8, 2024 (Wegovy injection); the tablets got the same indication with their approval on December 22, 2025 (Wegovy tablets).[8]
How to Cite in Your Letter
"Clinical trials demonstrate that semaglutide 2.4mg achieves 14.9-16% weight loss at 68 weeks, significantly exceeding the 3-5% typically achieved through lifestyle modification alone. The SELECT trial showed a 20% reduction in major cardiovascular events, leading to FDA approval for cardiovascular risk reduction. These outcomes support the medical necessity of Wegovy for patients with obesity and weight-related comorbidities."
RESPONSES TO COMMON DENIAL REASONS
Counter-Arguments
Click each denial reason to see the strongest counter-argument:
"Weight loss is cosmetic"
Your response:
"Obesity is recognized as a chronic, relapsing disease by the American Medical Association (2013), World Health Organization, and CDC. It is associated with significantly increased risk of cardiovascular disease, type 2 diabetes, certain cancers, and premature mortality. The FDA approved Wegovy specifically for the treatment of obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities—not for cosmetic purposes. Furthermore, the FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection)), confirming its role as a medically necessary treatment."[10]
"Lifestyle modification not documented"
Your response:
"[Patient] has participated in supervised weight management for [X months], including reduced-calorie diet and increased physical activity, with [X%] weight loss that was not sustained. Clinical evidence demonstrates that lifestyle modification alone achieves only 3-5% sustained weight loss in most patients, while GLP-1 agonists (a class of weight loss medications) like semaglutide achieve 14.9-16% weight loss at 68 weeks."[11]
Attach: Provider notes documenting diet/exercise program participation, dates, and outcomes.
"BMI threshold not met"
Your response:
"[Patient]'s current BMI is [X] kg/m², documented on [date]. Per FDA labeling, Wegovy is indicated for adults with BMI ≥30, OR BMI ≥27 with at least one weight-related comorbid condition. [Patient] has the following documented comorbidities: [list with ICD-10 codes]."[9]
Attach: Current BMI documentation + historical weight trend + comorbidity diagnoses.
"Step therapy not completed"
Your response:
"[Patient] has previously tried the following weight management medications: [list with dates, doses, duration, outcomes]. [Drug] was discontinued due to [adverse effects/inefficacy/contraindication]. Requiring additional step therapy would delay necessary treatment for a serious chronic disease."
If contraindicated: Specify why (e.g., "phentermine contraindicated due to uncontrolled hypertension").
See our step therapy denial guide for more details.
"No documented comorbidities"
Your response:
"[Patient] has the following diagnosed weight-related conditions: • [Condition 1] (ICD-10: [code]), diagnosed [date] • [Condition 2] (ICD-10: [code]), diagnosed [date] Supporting documentation attached includes lab results, provider notes, and diagnostic studies confirming these conditions."
Common ICD-10 codes: Hypertension (I10), Type 2 diabetes (E11), Obstructive sleep apnea (G47.33), Dyslipidemia (E78.5), Cardiovascular disease (I20-I25)
IF YOUR APPEAL IS DENIED AGAIN
External Review
Don't Give Up After Internal Denial
External reviews have a higher success rate than internal appeals. An independent reviewer (not employed by your insurer) evaluates your case, and their decision is binding on your insurance company.[2]
How to Request External Review
- File within 4 months of your final internal denial (some states allow longer)
- Submit to your state insurance department or designated external review organization
- Include all documentation from your internal appeal
- Add any new evidence gathered since your first appeal
State Protections
| State | Key Protection | Notes |
|---|---|---|
| New York | Automatic external review | Strongest protections—specialist reviewer required |
| California | 72-hour response | SB 1120 requires physician (not algorithm) review |
| Texas | External review mandate | 72-hour expedited window available |
| Florida | ACA minimums | Federal protections apply |
All states must comply with Affordable Care Act (ACA) external review requirements: right to independent review, 45-day decision timeline (72 hours if expedited).[12]
COMMON QUESTIONS ABOUT APPEALS
Frequently Asked Questions
Insurers deny Wegovy as "not medically necessary" when they claim your documentation doesn't prove you meet their criteria. This often happens due to: missing BMI documentation, no documented comorbidities, insufficient lifestyle modification records, or step therapy requirements not met. Many denials are based on incomplete paperwork rather than true ineligibility.
For most commercial insurance: 180 days from the denial date.[3] For a Medicare drug plan (including Medicare Advantage): within 65 days from the date on the denial notice.[4] For external review (after internal denial): 4 months. Check your denial letter for your specific deadline—missing it means you'll need to submit a new prior authorization instead of an appeal.
65%+ of prior authorization appeals succeed when patients appeal with proper documentation. The key factors are complete documentation, strong clinical evidence, and directly addressing the specific denial reason. External reviews have even higher success rates, and their decisions are legally binding.
A Letter of Medical Necessity (LOMN) is a formal document from your healthcare provider explaining why a specific treatment is medically required for your condition. It includes your diagnosis, medical history, prior treatments, clinical evidence supporting the medication, and a clear statement that the treatment is necessary—not optional or cosmetic.
Yes. Under the Affordable Care Act, all patients have the right to external review after their internal appeal is denied. An independent reviewer (not employed by your insurer) will evaluate your case. You typically have 4 months to request external review, and the decision is binding on your insurance company.
Yes. The FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)). The SELECT trial showed a 20% reduction in major cardiovascular events. This indication can strengthen medical necessity arguments and may provide an alternative coverage pathway if weight loss drugs are excluded.
Several states now require that a qualified physician—not an algorithm—review medical necessity denials. California's SB 1120 (2025) specifically prohibits AI-only denials. If you suspect algorithmic denial, request documentation of who reviewed your case and cite applicable state laws in your appeal.
YOUR PATH FORWARD
What's Next
Ready to Appeal?
65%+ of appeals succeed with proper documentation.[2] Our complete Wegovy appeals guide walks you through the entire process—from writing your appeal letter to requesting external review.
Other Common Denial Reasons
Denied for a different reason? See our guides for other denial types:
- Step Therapy Required — Must try other medications first
- BMI Criteria Not Met — Weight thresholds not satisfied
- Formulary Exclusion — Drug not on plan's covered list
Not sure why you were denied? View all Wegovy denial types →
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedWHAT'S CHANGING
Medical Necessity Denials: 2026 Outlook
2026: Documentation Requirements Increasing
Insurers are requiring more comprehensive documentation to establish medical necessity. Expect to provide detailed weight history, comorbidity records, and prior treatment documentation.
What Strengthens Medical Necessity
For 2026 appeals, focus on:
- Clinical evidence: STEP trial data showing 14.9-16% weight loss
- Cardiovascular benefit: SELECT trial showing 20% reduction in heart attacks and strokes
- AMA recognition: Obesity classified as disease since 2013
- Comorbidity impact: Document how weight affects your other conditions
- Failed alternatives: Evidence that other treatments didn't work
Wegovy-Specific Advantages for Appeals
Cardiovascular Indication: Wegovy is FDA-approved for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)). If your plan excludes weight loss drugs but you have established cardiovascular disease, the CV indication may provide an alternative coverage pathway.
CVS Caremark Preferred: Wegovy is CVS Caremark's preferred GLP-1 for weight loss. If your plan uses CVS Caremark, approval may be easier than for other GLP-1 medications.
If Appeals Fail: Self-Pay Option
NovoCare self-pay program doesn't require proving medical necessity—just a prescription:
- Injectable: $199/month for the first two fills (0.25 mg and 0.5 mg), through December 31, 2026, then $349/month ($399 for Wegovy HD 7.2 mg)
- Oral pill: $149–$299/month (available since January 5, 2026)
Medical Necessity Denials for Other GLP-1s
Similar denial? The appeal strategies are comparable across medications:
References
- HMP Global Learning Network. (2025). "GLP-1 Access Barriers Persist Despite Gradual Improvements in Payer Coverage." hmpgloballearningnetwork.com
- American Medical Association. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" 81% of Medicare Advantage appeals succeed; we use a conservative 65%+ estimate for commercial insurance. ama-assn.org
- HealthCare.gov. "Internal Appeals." healthcare.gov
- Centers for Medicare & Medicaid Services. "Medicare Prescription Drug Appeals & Grievances." cms.gov
- Novo Nordisk. (2025). "Wegovy Coverage Resources for Healthcare Providers." novoMEDLINK. novomedlink.com
- Obesity Action Coalition. "Appealing a Denied Prior Authorization." obesityaction.org
- Wilding JPH, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. STEP 1 trial. PubMed
- Lincoff AM, et al. (2023). "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." SELECT trial. N Engl J Med. PubMed
- U.S. Food and Drug Administration. (2024). "Wegovy Prescribing Information." fda.gov
- American Medical Association. (2013). "AMA Adopts New Policies on Second Day of Voting at Annual Meeting." Resolution 420 recognizing obesity as a disease. ama-assn.org
- American Association of Clinical Endocrinologists. (2023). "Clinical Practice Guidelines for the Management of Obesity." aace.com
- Counterforce Health. (2025). "State by State Guide to New Insurance Appeal Laws." counterforcehealth.org
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.